The clinical effect and safety on budesonide combined with ipratropium bromide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
10.3760/cma.j.issn.1008-6706.2015.19.036
- VernacularTitle:布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病急性发作临床疗效及安全性研究
- Author:
Jufang JIANG
;
Lihua MA
;
Jian DING
- Publication Type:Journal Article
- Keywords:
Pulmonary disease,chronic obstructive;
Budesonide;
Ipratropium bromide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(19):2996-2999
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of budesonide combined with ipratropium bromide in the treat-ment of acute exacerbations of chronic obstructive pulmonary disease,and observe the adverse reactions during treat-ment.To analyze the treatment of safety and to provide the basis for clinical treatment.Methods 160 cases of acute exacerbations of chronic obstructive pulmonary disease were selected,they were randomly divided into the control group A,B,C and the observation group,with 40 cases in each group.The control group A was treated with prednisone and other conventional,control group B was treated with aminophylline and other conventional treatment,the control group C application included prednisone,aminophylline and other conventional treatment,all the control group were treated with 0.9% sodium chloride solution inhaled as a placebo spray.And the observation group application of budesonide was combined with ipratropium bromide based on the routine treatment.Mainly the effect of treatment was observed,and the blood carbon dioxide partial pressure (PaO2 ),partial pressure of oxygen (PaCO2 ),forced expiratory volume in one second (FEV1 ),forced expiratory volume in one second (FEV1 )and forced expiratory volume in one second to forced vital capacity ratio of FVC (FEV1 /FVC)before and after treatment were detected.And the adverse reactions were observed to evaluate its safety.Results The total effective rate of the observation group was 95.00%(38 /40),which were higher than the control group A,B and C,the differences were statistically significant (χ2 =9.68,9.70,9.91,all P <0.05).The PaO2 level of the observation group after treatment was (76.89 ±0.63)mmHg, which were higher than that of the control group after treatment (73.66 ±0.47)mmHg,and that of two groups after treatment were higher than those before treatment,the differences were statistically significant (t =10.48,13.72,12.83,all P <0.05).The PaCO2 of the observation group after treatment was (50.06 ±0.60)mmHg,which were lower than that of the control group A,B and C after the treatment,each group after treatment was lower than that before treatment,the differences were statistically significant (t =11.72,12.69,10.74,all P <0.05 ).FEV1 and FEV1 /FVC of the observation group after treatment were (2.19 ±0.29)L and (69.27 ±0.59)%,which were higher than those of the control group A,B and C after treatment,and each groupafter treatment was higher than that before treatment,the differences were statistically significant (t =12.68,13.10,12.41,9.89,10.63,11.29,all P <0.05). Comparison of adverse reactions in each group,the difference was not statistically significant (χ2 =1.38,P >0.05). Conclusion It has good clinical curative effect on budesonide combined with ipratropium bromide for the treatment of acute exacerbations of chronic obstructive pulmonary disease patients,which can significantly improve the pulmona-ry function of patients,shorten recovery time,and has high security.It is worthy of clinical application.
